EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Small-Molecule Allosteric Modulators of Beta-Galactosidase (β-Gal) for the Treatment of GM1 Gangliosidosis and Morquio B

Natàlia Pérez-Carmona, Elena Cubero iD, Ana Ruano, Maria Pons-Vizcarra iD, Aida Delgado iD, Ana Trapero iD, Marc Reves, Laura Rodríguez-Pascau iD, Joanne Taylor, Marc Martinell, Xavier Barril iD, Ana María García-Collazo iD

International Journal of Molecular Sciences · 18.04.2026 · 27 (8) · 3631

DOI: 10.3390/ijms27083631 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.04.2026. Verfasst von Natàlia Pérez-Carmona und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gain Therapeutics Sucursal en España, Parc Científic de Barcelona, 08028 Barcelona, Spain. Hauptthemen laut MEDLINE: beta-Galactosidase, Gangliosidosis, GM1, Mucopolysaccharidosis IV, Small Molecule Libraries. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GM1 gangliosidosis and Morquio B are rare lysosomal storage disorders (LSDs) with significant unmet medical needs. These disorders result from mutations in the galactosidase beta 1 (GLB1) gene, leading to impaired β-galactosidase (β-Gal) activity and toxic substrate accumulation. The lack of approved disease-modifying therapies for GM1 gangliosidosis and Morquio B, along with the challenges of achieving effective central nervous system delivery, has driven interest in small-molecule pharmacological chaperones (PCs) to restore β-Gal stability and function. Using Gain Therapeutics’ Magellan™ platform, a novel allosteric binding site on β-Gal was identified, enabling the discovery of a new class of Structurally Targeted Allosteric Regulators (STARs). Medicinal chemistry optimization produced a structurally unique STAR compound series, demonstrating broad β-Gal stabilizing effects. The therapeutic potential of these compounds was evaluated in vitro using a canine fibroblast model of GM1 gangliosidosis, where they were shown to significantly reduce toxic GM1 ganglioside accumulation. Immunocytochemistry-based assays confirmed substrate clearance and provided reliable structure–activity relationships, guiding further compound development. Notably, STARs achieved greater substrate clearance than the competitive PC N-nonyl-deoxygalactonojirimycin (NN-DGJ) under the conditions tested, as demonstrated by immunocytochemistry-based assays. While these findings are encouraging, further in vivo studies are required to validate the therapeutic efficacy of these few STAR compounds, particularly in addressing the neurodegenerative aspects of GM1 gangliosidosis. This study underscores the potential of the Magellan platform in identifying STAR molecules and provides a strong foundation for further optimization and preclinical validation in GLB1-related disorders, particularly GM1 gangliosidosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-GalactosidaseGangliosidosis, GM1Mucopolysaccharidosis IVSmall Molecule LibrariesAnimalsAllosteric RegulationDogsFibroblastsHumansStructure-Activity RelationshipAllosteric Site

Stichwörter der Autor:innen

GLB1GM1-gangliosidosisMagellan platformbeta-galactosidaselysosomal storage disorderspharmacological chaperoneprotein misfoldingsite-directed enzyme enhancement therapy (SEE-Tx)structurally targeted allosteric regulators (STARs)substrate depletion

Substanzen

beta-GalactosidaseSmall Molecule Libraries

Autor:innen und Institutionen

  • Gain Therapeutics Sucursal en España, Parc Científic de Barcelona, 08028 Barcelona, Spain.
  • Minoryx Therapeutics, 08302 Barcelona, Spain.
  • Gain Therapeutics, Inc., Bethesda, MD 20814, USA.
  • Facultat de Farmàcia, IBUB & IQTC, Universitat de Barcelona, 08028 Barcelona, Spain.
  • Catalan Institution for Research and Advanced Studies (ICREA), 08010 Barcelona, Spain.

ORCID-Profile: Elena Cubero, Maria Pons-Vizcarra, Aida Delgado, Ana Trapero, Laura Rodríguez-Pascau, Xavier Barril, Ana María García-Collazo

Zitieren

APA

Pérez-Carmona, N., Cubero, E., Ruano, A., Pons-Vizcarra, M., Delgado, A., Trapero, A., Reves, M., Rodríguez-Pascau, L., Taylor, J., Martinell, M., Barril, X., & García-Collazo, A. M. (2026). Development of Small-Molecule Allosteric Modulators of Beta-Galactosidase (β-Gal) for the Treatment of GM1 Gangliosidosis and Morquio B. International Journal of Molecular Sciences, 27(8), 3631. https://doi.org/10.3390/ijms27083631

Vancouver

Pérez-Carmona N, Cubero E, Ruano A, Pons-Vizcarra M, Delgado A, Trapero A, et al. Development of Small-Molecule Allosteric Modulators of Beta-Galactosidase (β-Gal) for the Treatment of GM1 Gangliosidosis and Morquio B. International Journal of Molecular Sciences. 2026;27(8):3631. doi:10.3390/ijms27083631

BibTeX
@article{PrezCarmona2026,
  author = {Pérez-Carmona, Natàlia and Cubero, Elena and Ruano, Ana and Pons-Vizcarra, Maria and Delgado, Aida and Trapero, Ana and Reves, Marc and Rodríguez-Pascau, Laura and Taylor, Joanne and Martinell, Marc and Barril, Xavier and García-Collazo, Ana María},
  title = {Development of Small-Molecule Allosteric Modulators of Beta-Galactosidase (β-Gal) for the Treatment of GM1 Gangliosidosis and Morquio B},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {8},
  pages = {3631},
  doi = {10.3390/ijms27083631}
}
Kostenlos starten →